BioSyent Inc. (RX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the BioSign Inc. Q1 2026 results presentation. My name is René Goehrum and I'm the president and CEO of the company. I want to draw your attention to our forward-looking statements disclaimer, as I'm sure there will be some in today's presentation. The last several months have been quite an exciting time at BioSign. Within a span of less than three months, We announced a significant acquisition. We closed it. We started operating the new business and are now reporting our Q1 results, including one month of revenue and profit from that acquisition. On March 1st of this year, we acquired Oral Science and its wholly owned subsidiary, Oral Science International. I'll take a few moments to refresh you on the business and some of the details around it. Oral Science is a Canadian distributor of specialized healthcare products for dental hygiene and oral health. We purchased the business for $25.5 million. That price included $6.3 million of working capital. At close, there were $2 million of excess working capital in the business and we paid for that per the agreement that we had with the selling shareholders. In addition to the purchase price, there is a performance earnout, which you will see we are providing for paying an amount in the future. That payment will be made in 2027 based on the performance of the business, which based on the formula that we created on acquisition, we have every expectation that will be some further payment made on the performance element, which we are delighted based on the performance of the business. And then there's a royalty on the future sales of one additional product that's included that becomes an ongoing expense in the future against the cost of goods. So the purchase price and the fiscal 2025 financial results o...